Trial site
Kansas City VA Medical Center
Kansas City, Missouri 64128, United StatesNot linked to an institution yet
- 16running trials
- 2closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 22 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting10 trials
- Recruiting5 trials
- Completed2 trials
- Not yet recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Novartis Pharmaceuticals3 trials
- Boehringer Ingelheim2 trials
- Candel Therapeutics, Inc.2 trials
- Hoffmann-La Roche2 trials
- Midwest Biomedical Research2 trials
- and 8 more
Running trials
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085· Phase 1· Hoffmann-La Roche· Source
Active, not recruiting
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Contact: Trial Registration Coordinator
Active, not recruiting
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207· Phase 3· Novo Nordisk A/S· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974· Phase 2· Gilead Sciences· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553· Exact Sciences Corporation· Source
Active, not recruiting
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
NCT02768363· Phase 2· Candel Therapeutics, Inc.· Source
Active, not recruiting
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01436968· Phase 3· Candel Therapeutics, Inc.· Source
Recruiting
Barrett's Esophagus Related Neoplasia (BERN) Project
NCT00590239· Midwest Biomedical Research· Source
Contact: April Higbee, RN
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error